Belvedere Trading’s Moderna MRNA Stock Holding History

Belvedere Trading’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-703	Closed	-$69.9K	–	856
2023 Q4	$69.9K	Sell	703 -366	-34%	-$30.8K	﹤0.01%	523
2023 Q3	$110K	Buy	+1,069	New	+$119K	﹤0.01%	316

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's MRNA Position: Q1 2024 in Review

Belvedere Trading sold out of Moderna (MRNA) in Q1 2024, closing a stake of 703 shares — an estimated $69.9K sold.

Belvedere Trading first reported a position in MRNA in Q3 2023 and held it in 2 quarters. The position peaked at $110K in Q3 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

Belvedere Trading reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
Belvedere Trading sold 703 Moderna shares in Q1 2024, an estimated $69.9K.
Belvedere Trading first reported a position in Moderna in Q3 2023 and held it in 2 quarters.
Belvedere Trading's Moderna position peaked at $110K in Q3 2023.
902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.